{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-036386","form_type":"8-K","ticker":"CRDF","cik":"0001213037","company_name":"Cardiff Oncology, Inc.","filed_at":"2023-11-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.444963+00:00","generated_at":"2026-06-08T23:27:33.056207+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Cardiff Oncology shifts lead mCRC program to first-line; Q3 cash $81.4M","bullets":["Lead onvansertib program advances to first-line RAS-mutated mCRC; Pfizer Ignite to execute Phase 2 CRDF-004 trial.","FDA agreed on ORR as interim endpoint for accelerated approval; Phase 3 registrational trial planned contingent on CRDF-004.","mPDAC CRDF-001: ORR 19% (4/21 evaluable) vs historical 7.7%; mPFS 5.0 mo vs 3.1 mo for SoC alone.","Phase 2 SCLC monotherapy cleared to continue enrollment after safety review of first six patients.","Cash, equivalents, and short-term investments $81.4M; net cash burn Q3 $8.0M; runway into 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-036386","json":"https://secwatch.observer/filing/0001628280-23-036386.json","markdown":"https://secwatch.observer/filing/0001628280-23-036386.md","text":"https://secwatch.observer/filing/0001628280-23-036386.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1213037/000162828023036386/0001628280-23-036386-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1213037/000162828023036386/crdf-20231102.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T23:27:33.056207+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b0435554de6ec22ec35504953bb38decafa6529b","claim":"Cardiff Oncology, Inc. reported financial results for third quarter ended September 30, 2023.","evidence_excerpt":"On November 2, 2023, Cardiff Oncology, Inc. issued a press release announcing company highlights and financial results for the third quarter ended September 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1213037/000162828023036386/0001628280-23-036386-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}